SAFETY OF OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS OVER TIME: POOLED ANALYSIS FROM PHASE 2, PHASE 3, AND OPEN-LABEL EXTENSION TRIALS

被引：0
|
作者：
D'Haens, Geert R.
Colombel, Jean Frederic
Lichtenstein, Gary R.
Charles, Lorna
Petersen, AnnKatrin
Ather, Shabana
Kollengode, Kanthi
Hsu, Kate
Irving, Peter M.
Danese, Silvio
机构：
来源：
GASTROENTEROLOGY | 2021年 / 160卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
128
引用
收藏
页码：S35 / S35
页数：1
相关论文
共 50 条
  • [1] Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2TOUCHSTONE Study
    Sandborn, William J.
    Feagan, Brian G.
    Hanauer, Stephen
    Vermeire, Severine
    Ghosh, Subrata
    Liu, Wenzhong J.
    Petersen, AnnKatrin
    Charles, Lorna
    Huang, Vivian
    Usiskin, Keith
    Wolf, Douglas C.
    D'Haens, Geert
    JOURNAL OF CROHNS & COLITIS, 2021, 15 (07): : 1120 - 1129
  • [2] LONG-TERM SAFETY OF 3 YEARS OF OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION
    Abreu, Maria T.
    Danese, Silvio
    Wolf, Douglas C.
    Canavan, James B.
    Jain, Anjali
    Wu, Hsiuanlin
    Petersen, AnnKatrin
    Charles, Lorna
    Afzali, Anita
    Panaccione, Remo
    GASTROENTEROLOGY, 2023, 164 (06) : S208 - S208
  • [3] Long-term safety of 3 years of ozanimod in moderately to severely active ulcerative colitis: an interim analysis of the True North open-label extension
    Panaccione, R.
    Danese, S.
    Wolf, D. C.
    Canavan, J. B.
    Jain, A.
    Wu, H.
    Petersen, A.
    Charles, L.
    Afzali, A.
    Abreu, M. T.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 534 - 534
  • [4] Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension
    Danese, Silvio
    Panaccione, Remo
    Abreu, Maria T.
    Rubin, David T.
    Ghosh, Subrata
    Dignass, Axel
    Afzali, Anita
    Wolf, Douglas C.
    Chiorean, Michael, V
    Vermeire, Severine
    Jain, Anjali
    Charles, Lorna
    Lawlor, Garrett
    Osterman, Mark T.
    Wu, Hsiuanlin
    Canavan, James B.
    Petersen, Annkatrin
    Colombel, Jean-Frederic
    Regueiro, Miguel
    JOURNAL OF CROHNS & COLITIS, 2024, 18 (02): : 264 - 274
  • [5] EXTENDED THERAPY WITH OZANIMOD FOR DELAYED RESPONDERS TO OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
    Panaccione, Remo
    Afzali, Anita
    Hudesman, David
    Lawlor, Garrett
    Osterman, Mark T.
    Eren, Devrim
    Memaj, Arteid
    Regueiro, Miguel D.
    Ghosh, Subrata
    GASTROENTEROLOGY, 2022, 162 (07) : S965 - S965
  • [6] Safety of long-term ozanimod treatment for up to 4 years in patients with moderately to severely active Ulcerative Colitis: an interim analysis of the True North open-label extension
    Siegel, C.
    Danese, S.
    Rubin, D. T.
    Sabino, J.
    Long, M. D.
    Cross, R. K.
    Armuzzi, A.
    Blumenstein, I.
    Kobayashi, T.
    Lama, S.
    Charles, L.
    Cetin, V.
    Petersen, A.
    Wu, H.
    Wang, D.
    Jain, A.
    D'Haens, G.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I100 - I101
  • [7] Safety patterns with ozanimod in phase 3 and open-label extension trials in patients with relapsing multiple sclerosis
    Selmaj, K. W.
    Ziemssen, T.
    Comi, G.
    Hartung, H. P.
    Singal, M.
    Thorpe, A.
    Riolo, J. V.
    Cheng, C. Y.
    Sheffield, J. K.
    Krakovich, A.
    Vermersch, P.
    Cree, B. A. C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 324 - 324
  • [8] RECAPTURE OF RESPONSE WITH OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO WITHDREW THERAPY: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
    Afzali, Anita
    Chiorean, Michael V.
    Lawlor, Garrett
    Osterman, Mark T.
    Eren, Devrim
    Memaj, Arteid
    Panaccione, Remo
    Ghosh, Subrata
    GASTROENTEROLOGY, 2022, 162 (07) : S229 - S229
  • [9] Safety patterns with ozanimod during phase 3 and open-label extension trials in patients with relapsing multiple sclerosis
    Selmaj, K. W.
    Ziemssen, T.
    Comi, G.
    Hartung, H. -P.
    Singal, M.
    Riolo, J. V.
    Cheng, C. -Y.
    Sheffield, J. K.
    Minton, N.
    Vermersch, P.
    Cree, B. A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 641 - 642
  • [10] Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis: True North and Open-Label Extension Analyses
    Armuzzi, Alessandro
    Cross, Raymond K.
    Lichtenstein, Gary R.
    Hou, Jason
    Deepak, Parakkal
    Regueiro, Miguel
    Wolf, Douglas C.
    Akukwe, Lucy
    Ahmad, Harris A.
    Jain, Anjali
    Kozinn, Marc
    Wu, Hsiuanlin
    Petersen, AnnKatrin
    Charles, Lorna
    Long, Millie
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2024, 22 (05) : 1067 - 1076.e3
12345